nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—esophageal cancer	0.281	0.418	CbGaD
Afatinib—ABL1—esophageal cancer	0.219	0.325	CbGaD
Afatinib—EGFR—esophageal cancer	0.133	0.198	CbGaD
Afatinib—ABCB1—esophageal cancer	0.0405	0.0601	CbGaD
Afatinib—ABCG2—Carboplatin—esophageal cancer	0.0367	0.343	CbGbCtD
Afatinib—ABCG2—Cisplatin—esophageal cancer	0.0314	0.293	CbGbCtD
Afatinib—ABCG2—Methotrexate—esophageal cancer	0.0204	0.19	CbGbCtD
Afatinib—ABCB1—Cisplatin—esophageal cancer	0.0113	0.106	CbGbCtD
Afatinib—ABCB1—Methotrexate—esophageal cancer	0.00734	0.0686	CbGbCtD
Afatinib—Mucosal ulceration—Capecitabine—esophageal cancer	0.00649	0.129	CcSEcCtD
Afatinib—Skin fissures—Capecitabine—esophageal cancer	0.00446	0.0885	CcSEcCtD
Afatinib—ERBB2—exocrine gland—esophageal cancer	0.00445	0.114	CbGeAlD
Afatinib—ERBB2—neck—esophageal cancer	0.00284	0.0732	CbGeAlD
Afatinib—Pulmonary toxicity—Cisplatin—esophageal cancer	0.00279	0.0555	CcSEcCtD
Afatinib—Gefitinib—SBK1—esophageal cancer	0.00248	0.443	CrCbGaD
Afatinib—Paronychia—Methotrexate—esophageal cancer	0.00201	0.0398	CcSEcCtD
Afatinib—ERBB2—epithelium—esophageal cancer	0.00193	0.0498	CbGeAlD
Afatinib—ERBB4—epithelium—esophageal cancer	0.00193	0.0498	CbGeAlD
Afatinib—ERBB2—smooth muscle tissue—esophageal cancer	0.00186	0.048	CbGeAlD
Afatinib—Pulmonary toxicity—Methotrexate—esophageal cancer	0.00153	0.0304	CcSEcCtD
Afatinib—ERBB2—digestive system—esophageal cancer	0.00147	0.0379	CbGeAlD
Afatinib—IRAK1—bronchus—esophageal cancer	0.00142	0.0367	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—esophageal cancer	0.00139	0.0359	CbGeAlD
Afatinib—LCK—bronchus—esophageal cancer	0.00139	0.0358	CbGeAlD
Afatinib—PHKG2—lung—esophageal cancer	0.00137	0.0352	CbGeAlD
Afatinib—LCK—trachea—esophageal cancer	0.00125	0.0321	CbGeAlD
Afatinib—Blood potassium decreased—Capecitabine—esophageal cancer	0.00123	0.0244	CcSEcCtD
Afatinib—ERBB2—lung—esophageal cancer	0.00123	0.0316	CbGeAlD
Afatinib—ERBB4—lung—esophageal cancer	0.00123	0.0316	CbGeAlD
Afatinib—BLK—lymph node—esophageal cancer	0.00123	0.0316	CbGeAlD
Afatinib—DYRK1A—lung—esophageal cancer	0.00118	0.0305	CbGeAlD
Afatinib—EGFR—lung—esophageal cancer	0.00104	0.0268	CbGeAlD
Afatinib—Gefitinib—CHEK2—esophageal cancer	0.00097	0.173	CrCbGaD
Afatinib—PHKG2—lymph node—esophageal cancer	0.000935	0.0241	CbGeAlD
Afatinib—IRAK1—lung—esophageal cancer	0.000919	0.0237	CbGeAlD
Afatinib—LCK—lung—esophageal cancer	0.000896	0.0231	CbGeAlD
Afatinib—Mucosal inflammation—Capecitabine—esophageal cancer	0.000845	0.0168	CcSEcCtD
Afatinib—ERBB2—lymph node—esophageal cancer	0.00084	0.0216	CbGeAlD
Afatinib—DYRK1A—lymph node—esophageal cancer	0.000809	0.0208	CbGeAlD
Afatinib—ABL1—bronchus—esophageal cancer	0.000798	0.0205	CbGeAlD
Afatinib—Rhinorrhoea—Cisplatin—esophageal cancer	0.000783	0.0155	CcSEcCtD
Afatinib—ABL1—smooth muscle tissue—esophageal cancer	0.000781	0.0201	CbGeAlD
Afatinib—Infection—Carboplatin—esophageal cancer	0.000766	0.0152	CcSEcCtD
Afatinib—Keratitis—Capecitabine—esophageal cancer	0.000721	0.0143	CcSEcCtD
Afatinib—ABL1—trachea—esophageal cancer	0.000717	0.0184	CbGeAlD
Afatinib—EGFR—lymph node—esophageal cancer	0.000712	0.0183	CbGeAlD
Afatinib—Vandetanib—ABL1—esophageal cancer	0.000671	0.12	CrCbGaD
Afatinib—Mucosal inflammation—Methotrexate—esophageal cancer	0.000629	0.0125	CcSEcCtD
Afatinib—IRAK1—lymph node—esophageal cancer	0.000629	0.0162	CbGeAlD
Afatinib—ABL1—digestive system—esophageal cancer	0.000616	0.0159	CbGeAlD
Afatinib—LCK—lymph node—esophageal cancer	0.000613	0.0158	CbGeAlD
Afatinib—Body temperature increased—Carboplatin—esophageal cancer	0.00061	0.0121	CcSEcCtD
Afatinib—Rhinorrhoea—Capecitabine—esophageal cancer	0.000577	0.0115	CcSEcCtD
Afatinib—Vandetanib—KDR—esophageal cancer	0.00057	0.102	CrCbGaD
Afatinib—ABL1—lung—esophageal cancer	0.000515	0.0133	CbGeAlD
Afatinib—Interstitial lung disease—Methotrexate—esophageal cancer	0.000492	0.00976	CcSEcCtD
Afatinib—Dry eye—Capecitabine—esophageal cancer	0.000432	0.00857	CcSEcCtD
Afatinib—Dehydration—Cisplatin—esophageal cancer	0.000428	0.0085	CcSEcCtD
Afatinib—Mouth ulceration—Capecitabine—esophageal cancer	0.000423	0.00839	CcSEcCtD
Afatinib—Hypokalaemia—Cisplatin—esophageal cancer	0.000419	0.00832	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000415	0.00823	CcSEcCtD
Afatinib—Nasopharyngitis—Cisplatin—esophageal cancer	0.000412	0.00817	CcSEcCtD
Afatinib—Vandetanib—EGFR—esophageal cancer	0.000408	0.0727	CrCbGaD
Afatinib—Sepsis—Capecitabine—esophageal cancer	0.000406	0.00806	CcSEcCtD
Afatinib—Gefitinib—EGFR—esophageal cancer	0.000387	0.0691	CrCbGaD
Afatinib—Renal impairment—Capecitabine—esophageal cancer	0.000357	0.00708	CcSEcCtD
Afatinib—ABL1—lymph node—esophageal cancer	0.000352	0.00907	CbGeAlD
Afatinib—Renal failure—Cisplatin—esophageal cancer	0.000349	0.00692	CcSEcCtD
Afatinib—Stomatitis—Cisplatin—esophageal cancer	0.000346	0.00687	CcSEcCtD
Afatinib—Conjunctivitis—Cisplatin—esophageal cancer	0.000345	0.00685	CcSEcCtD
Afatinib—Cystitis noninfective—Methotrexate—esophageal cancer	0.00034	0.00675	CcSEcCtD
Afatinib—Cystitis—Methotrexate—esophageal cancer	0.000336	0.00667	CcSEcCtD
Afatinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000336	0.00666	CcSEcCtD
Afatinib—ABCG2—lung—esophageal cancer	0.000325	0.00836	CbGeAlD
Afatinib—Dehydration—Capecitabine—esophageal cancer	0.000316	0.00627	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—esophageal cancer	0.000315	0.00625	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—esophageal cancer	0.000315	0.00625	CcSEcCtD
Afatinib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000315	0.00625	CcSEcCtD
Afatinib—Connective tissue disorder—Cisplatin—esophageal cancer	0.000313	0.00621	CcSEcCtD
Afatinib—Urethral disorder—Cisplatin—esophageal cancer	0.000312	0.0062	CcSEcCtD
Afatinib—Dry skin—Capecitabine—esophageal cancer	0.000311	0.00618	CcSEcCtD
Afatinib—Hypokalaemia—Capecitabine—esophageal cancer	0.000309	0.00613	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000306	0.00607	CcSEcCtD
Afatinib—Nasopharyngitis—Capecitabine—esophageal cancer	0.000304	0.00603	CcSEcCtD
Afatinib—Sepsis—Methotrexate—esophageal cancer	0.000302	0.006	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000299	0.00594	CcSEcCtD
Afatinib—Eye disorder—Cisplatin—esophageal cancer	0.000298	0.00591	CcSEcCtD
Afatinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000287	0.0057	CcSEcCtD
Afatinib—Alopecia—Cisplatin—esophageal cancer	0.000281	0.00559	CcSEcCtD
Afatinib—Malnutrition—Cisplatin—esophageal cancer	0.000277	0.00551	CcSEcCtD
Afatinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000273	0.00541	CcSEcCtD
Afatinib—Muscle spasms—Cisplatin—esophageal cancer	0.000267	0.00529	CcSEcCtD
Afatinib—Weight decreased—Capecitabine—esophageal cancer	0.000265	0.00527	CcSEcCtD
Afatinib—Pneumonia—Capecitabine—esophageal cancer	0.000263	0.00522	CcSEcCtD
Afatinib—Infestation NOS—Capecitabine—esophageal cancer	0.000262	0.00519	CcSEcCtD
Afatinib—Infestation—Capecitabine—esophageal cancer	0.000262	0.00519	CcSEcCtD
Afatinib—Renal failure—Capecitabine—esophageal cancer	0.000257	0.0051	CcSEcCtD
Afatinib—Stomatitis—Capecitabine—esophageal cancer	0.000255	0.00506	CcSEcCtD
Afatinib—Urinary tract infection—Capecitabine—esophageal cancer	0.000254	0.00505	CcSEcCtD
Afatinib—Conjunctivitis—Capecitabine—esophageal cancer	0.000254	0.00505	CcSEcCtD
Afatinib—ABCB1—epithelium—esophageal cancer	0.000252	0.00649	CbGeAlD
Afatinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000247	0.00491	CcSEcCtD
Afatinib—Epistaxis—Capecitabine—esophageal cancer	0.000247	0.0049	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000234	0.00465	CcSEcCtD
Afatinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000232	0.0046	CcSEcCtD
Afatinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000231	0.00458	CcSEcCtD
Afatinib—Urethral disorder—Capecitabine—esophageal cancer	0.00023	0.00457	CcSEcCtD
Afatinib—Infection—Cisplatin—esophageal cancer	0.000225	0.00446	CcSEcCtD
Afatinib—ABCB1—trachea—esophageal cancer	0.000223	0.00574	CbGeAlD
Afatinib—ABCG2—lymph node—esophageal cancer	0.000222	0.00572	CbGeAlD
Afatinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000222	0.00441	CcSEcCtD
Afatinib—Skin disorder—Cisplatin—esophageal cancer	0.00022	0.00436	CcSEcCtD
Afatinib—Eye disorder—Capecitabine—esophageal cancer	0.000219	0.00436	CcSEcCtD
Afatinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000212	0.0042	CcSEcCtD
Afatinib—Alopecia—Capecitabine—esophageal cancer	0.000207	0.00412	CcSEcCtD
Afatinib—Mental disorder—Capecitabine—esophageal cancer	0.000206	0.00408	CcSEcCtD
Afatinib—Malnutrition—Capecitabine—esophageal cancer	0.000204	0.00406	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000203	0.00403	CcSEcCtD
Afatinib—Dyspnoea—Cisplatin—esophageal cancer	0.000202	0.00401	CcSEcCtD
Afatinib—Dysgeusia—Capecitabine—esophageal cancer	0.0002	0.00397	CcSEcCtD
Afatinib—Back pain—Capecitabine—esophageal cancer	0.000198	0.00393	CcSEcCtD
Afatinib—Decreased appetite—Cisplatin—esophageal cancer	0.000197	0.00391	CcSEcCtD
Afatinib—Muscle spasms—Capecitabine—esophageal cancer	0.000197	0.0039	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—esophageal cancer	0.000196	0.00389	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000195	0.00388	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—esophageal cancer	0.000195	0.00387	CcSEcCtD
Afatinib—Infestation—Methotrexate—esophageal cancer	0.000195	0.00387	CcSEcCtD
Afatinib—ABCB1—digestive system—esophageal cancer	0.000192	0.00494	CbGeAlD
Afatinib—Renal failure—Methotrexate—esophageal cancer	0.000191	0.0038	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—esophageal cancer	0.00019	0.00377	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—esophageal cancer	0.000189	0.00376	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000184	0.00366	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—esophageal cancer	0.000184	0.00365	CcSEcCtD
Afatinib—Body temperature increased—Cisplatin—esophageal cancer	0.000179	0.00355	CcSEcCtD
Afatinib—Cough—Capecitabine—esophageal cancer	0.000178	0.00354	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000173	0.00343	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000173	0.00343	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—esophageal cancer	0.000171	0.0034	CcSEcCtD
Afatinib—Infection—Capecitabine—esophageal cancer	0.000166	0.00329	CcSEcCtD
Afatinib—Nervous system disorder—Capecitabine—esophageal cancer	0.000164	0.00325	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—esophageal cancer	0.000163	0.00324	CcSEcCtD
Afatinib—Asthenia—Cisplatin—esophageal cancer	0.000162	0.00322	CcSEcCtD
Afatinib—Skin disorder—Capecitabine—esophageal cancer	0.000162	0.00322	CcSEcCtD
Afatinib—ABCB1—lung—esophageal cancer	0.00016	0.00412	CbGeAlD
Afatinib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000158	0.00313	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—esophageal cancer	0.000155	0.00307	CcSEcCtD
Afatinib—Alopecia—Methotrexate—esophageal cancer	0.000154	0.00307	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—esophageal cancer	0.000153	0.00304	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—esophageal cancer	0.000152	0.00302	CcSEcCtD
Afatinib—Insomnia—Capecitabine—esophageal cancer	0.000151	0.003	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—esophageal cancer	0.000149	0.00296	CcSEcCtD
Afatinib—Dyspnoea—Capecitabine—esophageal cancer	0.000149	0.00295	CcSEcCtD
Afatinib—Back pain—Methotrexate—esophageal cancer	0.000147	0.00292	CcSEcCtD
Afatinib—Dyspepsia—Capecitabine—esophageal cancer	0.000147	0.00292	CcSEcCtD
Afatinib—Decreased appetite—Capecitabine—esophageal cancer	0.000145	0.00288	CcSEcCtD
Afatinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000144	0.00286	CcSEcCtD
Afatinib—Vomiting—Cisplatin—esophageal cancer	0.000144	0.00286	CcSEcCtD
Afatinib—Fatigue—Capecitabine—esophageal cancer	0.000144	0.00286	CcSEcCtD
Afatinib—Rash—Cisplatin—esophageal cancer	0.000143	0.00283	CcSEcCtD
Afatinib—Constipation—Capecitabine—esophageal cancer	0.000143	0.00283	CcSEcCtD
Afatinib—Dermatitis—Cisplatin—esophageal cancer	0.000143	0.00283	CcSEcCtD
Afatinib—Nausea—Cisplatin—esophageal cancer	0.000134	0.00267	CcSEcCtD
Afatinib—Cough—Methotrexate—esophageal cancer	0.000133	0.00264	CcSEcCtD
Afatinib—Body temperature increased—Capecitabine—esophageal cancer	0.000132	0.00262	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000129	0.00255	CcSEcCtD
Afatinib—Infection—Methotrexate—esophageal cancer	0.000123	0.00245	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—esophageal cancer	0.000122	0.00242	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—esophageal cancer	0.000121	0.00239	CcSEcCtD
Afatinib—Asthenia—Capecitabine—esophageal cancer	0.00012	0.00238	CcSEcCtD
Afatinib—Pruritus—Capecitabine—esophageal cancer	0.000118	0.00234	CcSEcCtD
Afatinib—Gefitinib—ABCB1—esophageal cancer	0.000118	0.021	CrCbGaD
Afatinib—Diarrhoea—Capecitabine—esophageal cancer	0.000114	0.00227	CcSEcCtD
Afatinib—Insomnia—Methotrexate—esophageal cancer	0.000112	0.00223	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—esophageal cancer	0.000111	0.0022	CcSEcCtD
Afatinib—Dizziness—Capecitabine—esophageal cancer	0.00011	0.00219	CcSEcCtD
Afatinib—ABCB1—lymph node—esophageal cancer	0.000109	0.00282	CbGeAlD
Afatinib—Dyspepsia—Methotrexate—esophageal cancer	0.000109	0.00217	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—esophageal cancer	0.000108	0.00214	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000107	0.00213	CcSEcCtD
Afatinib—Fatigue—Methotrexate—esophageal cancer	0.000107	0.00213	CcSEcCtD
Afatinib—Vomiting—Capecitabine—esophageal cancer	0.000106	0.00211	CcSEcCtD
Afatinib—Rash—Capecitabine—esophageal cancer	0.000105	0.00209	CcSEcCtD
Afatinib—Dermatitis—Capecitabine—esophageal cancer	0.000105	0.00209	CcSEcCtD
Afatinib—Headache—Capecitabine—esophageal cancer	0.000105	0.00207	CcSEcCtD
Afatinib—Nausea—Capecitabine—esophageal cancer	9.91e-05	0.00197	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—esophageal cancer	9.82e-05	0.00195	CcSEcCtD
Afatinib—Asthenia—Methotrexate—esophageal cancer	8.91e-05	0.00177	CcSEcCtD
Afatinib—Pruritus—Methotrexate—esophageal cancer	8.79e-05	0.00174	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—esophageal cancer	8.5e-05	0.00169	CcSEcCtD
Afatinib—Dizziness—Methotrexate—esophageal cancer	8.21e-05	0.00163	CcSEcCtD
Afatinib—Vomiting—Methotrexate—esophageal cancer	7.9e-05	0.00157	CcSEcCtD
Afatinib—Rash—Methotrexate—esophageal cancer	7.83e-05	0.00155	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—esophageal cancer	7.82e-05	0.00155	CcSEcCtD
Afatinib—Headache—Methotrexate—esophageal cancer	7.78e-05	0.00154	CcSEcCtD
Afatinib—Nausea—Methotrexate—esophageal cancer	7.38e-05	0.00146	CcSEcCtD
Afatinib—ABCG2—Metabolism—PSME2—esophageal cancer	8.89e-06	7.13e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PSME1—esophageal cancer	8.89e-06	7.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—PIK3CA—esophageal cancer	8.87e-06	7.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADH7—esophageal cancer	8.86e-06	7.1e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLCE1—esophageal cancer	8.86e-06	7.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CASP8—esophageal cancer	8.79e-06	7.05e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	8.79e-06	7.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CREBBP—esophageal cancer	8.75e-06	7.02e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—XIAP—esophageal cancer	8.74e-06	7.01e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EGFR—esophageal cancer	8.72e-06	6.99e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ABL1—esophageal cancer	8.71e-06	6.98e-05	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	8.69e-06	6.97e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CDKN1A—esophageal cancer	8.66e-06	6.95e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—BCL2—esophageal cancer	8.66e-06	6.94e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOTCH1—esophageal cancer	8.63e-06	6.92e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNA1—esophageal cancer	8.57e-06	6.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—PIK3CA—esophageal cancer	8.55e-06	6.86e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFBR2—esophageal cancer	8.54e-06	6.85e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CDKN1A—esophageal cancer	8.53e-06	6.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL2—esophageal cancer	8.52e-06	6.84e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOTCH1—esophageal cancer	8.5e-06	6.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SMAD4—esophageal cancer	8.46e-06	6.79e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CDKN1A—esophageal cancer	8.41e-06	6.75e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—ERBB2—esophageal cancer	8.41e-06	6.74e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	8.36e-06	6.7e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—BCL2—esophageal cancer	8.34e-06	6.69e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNA1—esophageal cancer	8.26e-06	6.63e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EP300—esophageal cancer	8.24e-06	6.61e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFBR2—esophageal cancer	8.23e-06	6.6e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL2—esophageal cancer	8.21e-06	6.59e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—CDKN1A—esophageal cancer	8.2e-06	6.58e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EP300—esophageal cancer	8.12e-06	6.51e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ERBB2—esophageal cancer	8.1e-06	6.5e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SMAD4—esophageal cancer	8.08e-06	6.48e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ERBB2—esophageal cancer	8.08e-06	6.48e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—TLR4—esophageal cancer	8.01e-06	6.43e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EP300—esophageal cancer	8e-06	6.42e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—CDKN1A—esophageal cancer	7.99e-06	6.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PSME1—esophageal cancer	7.96e-06	6.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PSME2—esophageal cancer	7.96e-06	6.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ANXA1—esophageal cancer	7.92e-06	6.36e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—CDKN1A—esophageal cancer	7.88e-06	6.32e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CREBBP—esophageal cancer	7.82e-06	6.27e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—EP300—esophageal cancer	7.81e-06	6.26e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SMAD4—esophageal cancer	7.79e-06	6.24e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ERBB2—esophageal cancer	7.78e-06	6.24e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADH1B—esophageal cancer	7.77e-06	6.23e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—EP300—esophageal cancer	7.74e-06	6.21e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—esophageal cancer	7.72e-06	6.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SST—esophageal cancer	7.71e-06	6.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CREBBP—esophageal cancer	7.7e-06	6.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PSME2—esophageal cancer	7.67e-06	6.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PSME1—esophageal cancer	7.67e-06	6.15e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP1B1—esophageal cancer	7.67e-06	6.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ANXA1—esophageal cancer	7.64e-06	6.12e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—EP300—esophageal cancer	7.61e-06	6.1e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	7.6e-06	6.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—PIK3CA—esophageal cancer	7.57e-06	6.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—BCL2—esophageal cancer	7.54e-06	6.05e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GHRL—esophageal cancer	7.51e-06	6.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH3—esophageal cancer	7.51e-06	6.03e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—EP300—esophageal cancer	7.49e-06	6.01e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SST—esophageal cancer	7.43e-06	5.96e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMP—esophageal cancer	7.42e-06	5.95e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FBXW7—esophageal cancer	7.39e-06	5.93e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ERBB2—esophageal cancer	7.32e-06	5.88e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—EP300—esophageal cancer	7.32e-06	5.87e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	7.28e-06	5.84e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH3—esophageal cancer	7.24e-06	5.81e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GHRL—esophageal cancer	7.24e-06	5.81e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP26A1—esophageal cancer	7.22e-06	5.79e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP19A1—esophageal cancer	7.21e-06	5.78e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CDKN1A—esophageal cancer	7.19e-06	5.76e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	7.12e-06	5.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FBXW7—esophageal cancer	7.12e-06	5.71e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALOX15—esophageal cancer	7.04e-06	5.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—esophageal cancer	7.02e-06	5.63e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOS3—esophageal cancer	7e-06	5.62e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CDKN1A—esophageal cancer	6.93e-06	5.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HIF1A—esophageal cancer	6.92e-06	5.55e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—esophageal cancer	6.92e-06	5.55e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CDKN1A—esophageal cancer	6.9e-06	5.54e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOS3—esophageal cancer	6.9e-06	5.53e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CASP8—esophageal cancer	6.88e-06	5.51e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TLR4—esophageal cancer	6.85e-06	5.49e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CREBBP—esophageal cancer	6.84e-06	5.49e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—EP300—esophageal cancer	6.84e-06	5.49e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—esophageal cancer	6.82e-06	5.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH2—esophageal cancer	6.74e-06	5.4e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TPI1—esophageal cancer	6.71e-06	5.38e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTO1—esophageal cancer	6.71e-06	5.38e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—esophageal cancer	6.65e-06	5.34e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CDKN1A—esophageal cancer	6.65e-06	5.33e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—esophageal cancer	6.63e-06	5.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KDR—esophageal cancer	6.62e-06	5.31e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HIF1A—esophageal cancer	6.61e-06	5.3e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TLR4—esophageal cancer	6.6e-06	5.29e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EP300—esophageal cancer	6.59e-06	5.29e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—HMOX1—esophageal cancer	6.58e-06	5.28e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—PIK3CA—esophageal cancer	6.58e-06	5.27e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—esophageal cancer	6.53e-06	5.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH2—esophageal cancer	6.49e-06	5.21e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—esophageal cancer	6.48e-06	5.2e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ERBB2—esophageal cancer	6.45e-06	5.18e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALDOB—esophageal cancer	6.44e-06	5.16e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—esophageal cancer	6.39e-06	5.12e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HIF1A—esophageal cancer	6.37e-06	5.11e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—esophageal cancer	6.36e-06	5.1e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ABCB1—esophageal cancer	6.32e-06	5.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CDKN1A—esophageal cancer	6.26e-06	5.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOTCH1—esophageal cancer	6.24e-06	5e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GAPDH—esophageal cancer	6.2e-06	4.97e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	6.18e-06	4.96e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CRABP1—esophageal cancer	6.14e-06	4.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—PIK3CA—esophageal cancer	6.09e-06	4.89e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS2—esophageal cancer	6.01e-06	4.82e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—PIK3CA—esophageal cancer	6e-06	4.82e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	5.98e-06	4.8e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFBR2—esophageal cancer	5.98e-06	4.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EP300—esophageal cancer	5.96e-06	4.78e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOTCH1—esophageal cancer	5.96e-06	4.78e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—PIK3CA—esophageal cancer	5.92e-06	4.75e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—BCL2—esophageal cancer	5.9e-06	4.73e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CASP8—esophageal cancer	5.88e-06	4.71e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CREBBP—esophageal cancer	5.85e-06	4.69e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNG7—esophageal cancer	5.84e-06	4.68e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS2—esophageal cancer	5.8e-06	4.65e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—esophageal cancer	5.79e-06	4.64e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—PIK3CA—esophageal cancer	5.78e-06	4.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFBR2—esophageal cancer	5.76e-06	4.62e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOTCH1—esophageal cancer	5.74e-06	4.6e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB2—esophageal cancer	5.73e-06	4.6e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—esophageal cancer	5.7e-06	4.57e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CASP8—esophageal cancer	5.66e-06	4.54e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SMAD4—esophageal cancer	5.66e-06	4.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CREBBP—esophageal cancer	5.65e-06	4.54e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CREBBP—esophageal cancer	5.64e-06	4.52e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—PIK3CA—esophageal cancer	5.63e-06	4.51e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—esophageal cancer	5.62e-06	4.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CDKN1A—esophageal cancer	5.6e-06	4.49e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—PIK3CA—esophageal cancer	5.54e-06	4.45e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CDKN1A—esophageal cancer	5.51e-06	4.42e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALDH2—esophageal cancer	5.47e-06	4.39e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMAD4—esophageal cancer	5.45e-06	4.37e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CA—esophageal cancer	5.42e-06	4.34e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CREBBP—esophageal cancer	5.4e-06	4.33e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—esophageal cancer	5.39e-06	4.33e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EP300—esophageal cancer	5.33e-06	4.27e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EP300—esophageal cancer	5.25e-06	4.21e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—esophageal cancer	5.24e-06	4.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTT1—esophageal cancer	5.21e-06	4.17e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CREBBP—esophageal cancer	5.2e-06	4.17e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2A6—esophageal cancer	5.15e-06	4.13e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—esophageal cancer	5.08e-06	4.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—esophageal cancer	5.06e-06	4.06e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—esophageal cancer	5.06e-06	4.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2—esophageal cancer	5.04e-06	4.04e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDKN1A—esophageal cancer	4.9e-06	3.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—esophageal cancer	4.9e-06	3.93e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO1—esophageal cancer	4.88e-06	3.91e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS1—esophageal cancer	4.88e-06	3.91e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—esophageal cancer	4.88e-06	3.91e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.87e-06	3.91e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2—esophageal cancer	4.86e-06	3.9e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—esophageal cancer	4.86e-06	3.9e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—esophageal cancer	4.83e-06	3.88e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PSME2—esophageal cancer	4.81e-06	3.85e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PSME1—esophageal cancer	4.81e-06	3.85e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—esophageal cancer	4.74e-06	3.8e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—esophageal cancer	4.72e-06	3.79e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—esophageal cancer	4.68e-06	3.75e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EP300—esophageal cancer	4.66e-06	3.74e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—esophageal cancer	4.66e-06	3.74e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—esophageal cancer	4.64e-06	3.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HIF1A—esophageal cancer	4.63e-06	3.71e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—esophageal cancer	4.57e-06	3.67e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—esophageal cancer	4.54e-06	3.64e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—esophageal cancer	4.52e-06	3.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—esophageal cancer	4.47e-06	3.59e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—esophageal cancer	4.46e-06	3.58e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—esophageal cancer	4.43e-06	3.55e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—esophageal cancer	4.42e-06	3.55e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—esophageal cancer	4.41e-06	3.53e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—esophageal cancer	4.36e-06	3.5e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—esophageal cancer	4.27e-06	3.42e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—esophageal cancer	4.26e-06	3.42e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CREBBP—esophageal cancer	4.22e-06	3.39e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—esophageal cancer	4.19e-06	3.36e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—esophageal cancer	4.18e-06	3.36e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—esophageal cancer	4.17e-06	3.35e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	4.15e-06	3.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—esophageal cancer	4.05e-06	3.25e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—esophageal cancer	4.03e-06	3.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	4.02e-06	3.22e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—EP300—esophageal cancer	3.98e-06	3.19e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—esophageal cancer	3.97e-06	3.19e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—esophageal cancer	3.94e-06	3.16e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	3.9e-06	3.13e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—esophageal cancer	3.88e-06	3.11e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—esophageal cancer	3.86e-06	3.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EP300—esophageal cancer	3.85e-06	3.09e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EP300—esophageal cancer	3.84e-06	3.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—esophageal cancer	3.81e-06	3.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREBBP—esophageal cancer	3.78e-06	3.03e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—esophageal cancer	3.78e-06	3.03e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—esophageal cancer	3.76e-06	3.01e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—esophageal cancer	3.72e-06	2.99e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—EP300—esophageal cancer	3.68e-06	2.95e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREBBP—esophageal cancer	3.64e-06	2.92e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—esophageal cancer	3.56e-06	2.85e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EP300—esophageal cancer	3.54e-06	2.84e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—esophageal cancer	3.46e-06	2.77e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—esophageal cancer	3.45e-06	2.77e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—esophageal cancer	3.39e-06	2.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—esophageal cancer	3.36e-06	2.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—esophageal cancer	3.28e-06	2.63e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—esophageal cancer	3.27e-06	2.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—esophageal cancer	3.26e-06	2.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—esophageal cancer	3.22e-06	2.59e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—esophageal cancer	3.2e-06	2.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—esophageal cancer	3.17e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—esophageal cancer	3.09e-06	2.48e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—esophageal cancer	3.05e-06	2.45e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—esophageal cancer	3.02e-06	2.42e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—esophageal cancer	2.95e-06	2.36e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—EP300—esophageal cancer	2.88e-06	2.31e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—esophageal cancer	2.85e-06	2.29e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—esophageal cancer	2.84e-06	2.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—esophageal cancer	2.8e-06	2.24e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—esophageal cancer	2.76e-06	2.21e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—esophageal cancer	2.72e-06	2.18e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—esophageal cancer	2.71e-06	2.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—esophageal cancer	2.7e-06	2.16e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—esophageal cancer	2.62e-06	2.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	2.61e-06	2.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EP300—esophageal cancer	2.58e-06	2.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EP300—esophageal cancer	2.48e-06	1.99e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CREBBP—esophageal cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—esophageal cancer	2.24e-06	1.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—esophageal cancer	2.16e-06	1.73e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—esophageal cancer	2.13e-06	1.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—esophageal cancer	2.12e-06	1.7e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—esophageal cancer	2.04e-06	1.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—esophageal cancer	1.91e-06	1.53e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—esophageal cancer	1.87e-06	1.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—esophageal cancer	1.84e-06	1.48e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	1.84e-06	1.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—esophageal cancer	1.78e-06	1.42e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—EP300—esophageal cancer	1.55e-06	1.25e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.15e-06	9.22e-06	CbGpPWpGaD
